新聞稿 | HIPRA

who we are

新聞稿

01/22/2025 - 08:00

HIPRA presents 'HIPRA Biotech Services', its new unit specialized in CDMO services for the development and manufacturing of biologicals for third parties

人類

06/26/2024 - 15:09

Significant advancements and a fifteen-month extension for the RBDCOV Project

人類

10/18/2023 - 16:14

BIMERVAX® becomes the first COVID-19 vaccine approved by WHO

人類

07/17/2023 - 14:43

AEMPS authorizes the clinical trial to study the joint vaccination of HIPRA's COVID-19 vaccine with an influenza vaccine

人類

07/03/2023 - 09:07

HIPRA signs agreement with the European Commission to ensure a rapid response to future pandemics

人類

05/29/2023 - 08:15

AEMPS authorizes the clinical trial to study HIPRA's COVID-19 vaccine in adolescents between 12 and 17 years old

人類